LOGO
LOGO

Intraday Alerts

Compass Therapeutics Plunges 63% Despite Positive Cancer Trial Data

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

Shares of Compass Therapeutics, Inc. (CMPX) tumbled sharply despite encouraging clinical results.

The stock is currently trading at $1.87, down $3.15 or 62.67%, on the Nasdaq. It opened at $1.76 after closing the previous session at $5.02. The stock has traded between $1.61 and $6.88 over the past 52 weeks.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update: April 20 – April 24, 2026

April 24, 2026 15:15 ET
Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.